Advancements in chikungunya virus management: FDA approval of ixchiq vaccine and global perspectives.
作者信息
Irfan Hamza, Ahmed Aliza
机构信息
Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Pakistan.
Department of Medicine Jinnah Sindh Medical University Karachi Pakistan.
出版信息
Health Sci Rep. 2024 Jun 21;7(6):e2183. doi: 10.1002/hsr2.2183. eCollection 2024 Jun.
Abstract
摘要
相似文献
1
Advancements in chikungunya virus management: FDA approval of ixchiq vaccine and global perspectives.基孔肯雅病毒管理的进展：美国食品药品监督管理局批准伊奇克疫苗及全球视角
Health Sci Rep. 2024 Jun 21;7(6):e2183. doi: 10.1002/hsr2.2183. eCollection 2024 Jun.
2
Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection.伊奇克（VLA1553）：首个获美国食品药品监督管理局批准用于预防基孔肯雅病毒感染所致疾病的疫苗。
Virulence. 2024 Dec;15(1):2301573. doi: 10.1080/21505594.2023.2301573. Epub 2024 Jan 13.
3
Live-attenuated chikungunya virus vaccine.活减毒基孔肯雅病毒疫苗。
Cell. 2024 Feb 15;187(4):813-813.e1. doi: 10.1016/j.cell.2024.01.033.
4
Drugs targeting structural and nonstructural proteins of the chikungunya virus: A review.靶向基孔肯雅病毒结构蛋白和非结构蛋白的药物：综述。
Int J Biol Macromol. 2024 Mar;262(Pt 2):129949. doi: 10.1016/j.ijbiomac.2024.129949. Epub 2024 Feb 2.
6
Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.预防基孔肯雅病毒所致疾病的疫苗研发中的监管考量
Vaccine. 2017 Sep 5;35(37):4851-4858. doi: 10.1016/j.vaccine.2017.07.065. Epub 2017 Jul 29.
7
Novel chikungunya and dengue vaccines: travel medicine applications.新型基孔肯雅热疫苗和登革热疫苗：旅行医学应用
J Travel Med. 2024 Jun 3;31(4). doi: 10.1093/jtm/taae064.
8
Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis.关于在有基孔肯雅热暴发风险的国家引入基孔肯雅热疫苗的规划考虑因素和证据缺口：利益攸关方分析。
PLoS Negl Trop Dis. 2024 Apr 4;18(4):e0012075. doi: 10.1371/journal.pntd.0012075. eCollection 2024 Apr.
9
A patent perspective on chikungunya.基孔肯雅热的专利视角。
Acta Trop. 2019 Nov;199:105131. doi: 10.1016/j.actatropica.2019.105131. Epub 2019 Aug 8.
10
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.基于麻疹病毒的基孔肯雅病毒疫苗 MV-CHIK 的免疫原性、安全性和耐受性：一项双盲、随机、安慰剂对照和阳性对照的 2 期临床试验。
Lancet. 2019 Dec 22;392(10165):2718-2727. doi: 10.1016/S0140-6736(18)32488-7. Epub 2018 Nov 5.
引用本文的文献
1
Chikungunya virus: from genetic adaptation to pandemic risk and prevention.基孔肯雅病毒：从基因适应到流行风险与预防
Ther Adv Infect Dis. 2025 Aug 30;12:20499361251371110. doi: 10.1177/20499361251371110. eCollection 2025 Jan-Dec.
2
Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ).减毒活基孔肯雅病毒疫苗（IXCHIQ）反应原性和安全性的综合评估
Vaccines (Basel). 2025 May 28;13(6):576. doi: 10.3390/vaccines13060576.
3
In Vitro Evaluation of the Anti-Chikungunya Virus Activity of an Active Fraction Obtained from Latex.从乳胶中获得的活性组分抗基孔肯雅病毒活性的体外评价
Viruses. 2024 Dec 17;16(12):1929. doi: 10.3390/v16121929.
4
The potential inhibitory mechanism of EGCG against the Chikungunya virus targeting non-structural protein 2 through molecular dynamics simulation.EGCG 对基孔肯雅病毒非结构蛋白 2 的潜在抑制机制：基于分子动力学模拟的研究。
Sci Rep. 2024 Nov 30;14(1):29797. doi: 10.1038/s41598-024-81287-0.
本文引用的文献
1
Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need.关于研发基孔肯雅病毒疫苗及确保有需要国家公平获取疫苗的战略考量。
NPJ Vaccines. 2023 Aug 18;8(1):123. doi: 10.1038/s41541-023-00722-x.
2
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.一种单次接种的减毒活寨卡病毒疫苗的安全性和免疫原性：一项双盲、多中心、随机、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4. Epub 2023 Jun 12.
3
Analytical and Clinical Evaluation of a TaqMan Real-Time PCR Assay for the Detection of Chikungunya Virus.TaqMan 实时 PCR 法检测基孔肯雅病毒的分析和临床评估。
Microbiol Spectr. 2023 Aug 17;11(4):e0008823. doi: 10.1128/spectrum.00088-23. Epub 2023 Jun 5.
4
A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.一项评估基于 mRNA 的基孔肯雅病毒疫苗在健康成年人中的安全性和免疫原性的 1 期、随机、安慰剂对照、剂量范围研究。
Vaccine. 2023 Jun 13;41(26):3898-3906. doi: 10.1016/j.vaccine.2023.04.064. Epub 2023 May 18.
5
Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.PXVX0317，一种含氢氧化铝佐剂的基孔肯雅病毒样颗粒疫苗的安全性和免疫原性：一项随机、双盲、平行组、2 期临床试验。
Lancet Infect Dis. 2022 Sep;22(9):1343-1355. doi: 10.1016/S1473-3099(22)00226-2. Epub 2022 Jun 13.
6
The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines.1999 年至 2020 年全球基孔肯雅热流行病学：系统文献综述以提供疫苗开发和引入的信息。
PLoS Negl Trop Dis. 2022 Jan 12;16(1):e0010069. doi: 10.1371/journal.pntd.0010069. eCollection 2022 Jan.
7
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.一项针对脂质包裹的编码具有中和抗基孔肯雅病毒活性的单克隆抗体的 mRNA 的 1 期临床试验。
Nat Med. 2021 Dec;27(12):2224-2233. doi: 10.1038/s41591-021-01573-6. Epub 2021 Dec 9.
8
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.在一项 1 期临床试验中，单次接种 ChAdOx1 Chik 疫苗可诱导针对 4 种基孔肯雅病毒谱系的中和抗体。
Nat Commun. 2021 Jul 30;12(1):4636. doi: 10.1038/s41467-021-24906-y.
9
Chikungunya virus in Asia - Pacific: a systematic review.亚太地区的基孔肯雅热病毒：系统评价。
Emerg Microbes Infect. 2019;8(1):70-79. doi: 10.1080/22221751.2018.1559708.
10
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.基于麻疹病毒的基孔肯雅病毒疫苗 MV-CHIK 的免疫原性、安全性和耐受性：一项双盲、随机、安慰剂对照和阳性对照的 2 期临床试验。
Lancet. 2019 Dec 22;392(10165):2718-2727. doi: 10.1016/S0140-6736(18)32488-7. Epub 2018 Nov 5.
Zotero 插件